Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sirolimus-eluting coronary stent - REVA Medical

Next Previous
Drug Profile

Sirolimus-eluting coronary stent - REVA Medical

Alternative Names: Fantom; Fantom bioresorbable vascular scaffold; Fantom Encore; ReZolve; ReZolve Scaffold; ReZolve2

Latest Information Update: 20 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator REVA Medical
  • Class Anti-infectives; Anti-inflammatories; Antiepileptic drugs; Antifungals; Antineoplastics; Cardiovascular therapies; Eye disorder therapies; Lactones; Macrolides; Nootropics; Polyenes; Pyridines; Skin disorder therapies
  • Mechanism of Action Immunosuppressants; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Coronary artery restenosis

Most Recent Events

  • 30 Sep 2024 REVA Medical completes a FANTOM II trial for Coronary artery restenosis in Australia, Belgium, Brazil, France, Germany, the Netherlands, Poland and Denmark(Intracoronary) (NCT02539966)
  • 04 Apr 2023 No development reported - Clinical-Phase-Unknown for Coronary artery restenosis in Brazil (Intracoronary)
  • 30 Apr 2020 REVA Medical completes FANTOM I trial for Fantom™ bioresorbable coronary scaffold in native coronary arteries in Brazil and Poland (NCT02512003)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top